UTHR
UNITED THERAPEUTICS Corp
NASDAQ · Healthcare · Biotechnology · US
$543.15
+1.88%Year over year
Reported trailing growth
- Revenue
- +2.5%
- EBITDA
- -2.3%
- EBIT
- -3.1%
- EPS
- +9.1%
- Free cash flow
- +2.1%
- Operating cash flow
- +22.9%
Forward estimates
Based on analyst estimates
- Revenue
- +4.0%
- EBITDA
- +8.8%
- EPS
- -5.6%
Three-year CAGR
- Revenue
- +18.0%
- EBITDA
- +20.5%
- EBIT
- +15.7%
- Net income
- +22.4%
- EPS
- +23.5%
- Free cash flow
- +16.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026